Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone versus prednisone plus methotrexate versus prednisone plus cyclosporine in new-onset juvenile dermatomyositis
NL-OMON23726Phase 3Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in juvenile dermatomyositis (JDM) comparing Prednisone alone, Prednisone plus methotrexate and Prednisone plus cyclosporine (3 arms). Primary endpoints: Responder rate by PRINTO definition of improvement, Time to clinical remission on medication and 2 more. Started Dec 2006; status: active, not recruiting.
02
Drugs
prednisonemethotrexatecyclosporine
03
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on NL-OMON23726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23726.